Trevor Bossi

Trevor focuses his practice on the representation of issuers and investment banks across a variety of public and private capital markets transactions, including initial public offerings, at-the-market (ATM) facilities and other equity offerings, debt offerings, exchange and tender offers and more. Trevor also regularly advises domestic and foreign life sciences companies with respect to compliance with US securities laws and corporate governance matters.

Trevor also advises emerging companies on a wide range of corporate matters, including venture financings and mergers & acquisitions.

Representative company-side and underwriter-side representations:

• VectivBio – acquisition by Ironwood Pharmaceuticals pursuant to a $1 billion tender offer
• Autolus Therapeutics –strategic collaboration with BioNTech; $350 million registered direct offering; $150 million follow on offering and public company representation
• Immunovant, Inc. – $492 million follow on offering and concurrent private placement; $75.0 million underwritten offering, $150 million at-the-market facility and public company representation
• Immunocore - $350 million convertible notes offering
• Nanobiotix - represented in the underwriters in $54 million follow on offering and concurrent private placement
• Oculis - $220 million deSPAC, $42.5 million follow on offering and public company representation
• Repare Therapeutics – $88.0 million follow on offering, $125 million at-the-market facility and public company representation
• Valneva SE – $99.9 million global offering of American depositary shares in the United States and concurrent private placement of ordinary shares in Europe, $75 million at-the-market facility and public company representation
• Calliditas Therapeutics - $75 million at-the-market facility (first US at-the-market facility for a Swedish company) and public company representation
• Addex Therapeutics – July 2022 and March 2023 registered direct offerings of American depositary shares and concurrent private placements of pre-funded and ordinary warrants, as well as public company representation
• Exicure – September 2022 private placement
• Eagle Pharmaceuticals – public company representation
• Gain Therapeutics - $16 million at-the-market facility and public company representation
• Nextdoor - $674 million deSPAC*
• Faraday Future - $3.4 billion deSPAC *
• Romeo Power - $1.33 billion deSPAC*
• Khosla Ventures - $300 million, $400 million and $500 million SPAC IPOs*

*matters handled prior to joining Cooley LLP